Hypercoagulability Treatment Market 2023 to 2033 | Development in R&D activities will drive Sector Growth

Posted by Ganesh Shinde on March 21st, 2023

The global hypercoagulability treatment market is predicted to generate a market value of US$ 670 million in 2023 and a market value of US$ 1,317.99 million by 2033, with a CAGR of 7% from 2023 to 2033. In the historical period 2018 to 2022, the market for Hypercoagulability Treatment grew at a CAGR of 4%.

The rising awareness about hypercoagulability and its consequences, along with the increasing incidence of conditions that increase the risk of hypercoagulability, are driving the growth of the hypercoagulability treatment market. The increasing demand for these treatments is expected to lead to the development of new and innovative treatments, which will drive the growth of the market in the coming years. The market is likely to witness significant growth due to the increasing prevalence of hypercoagulability and the increasing focus on improving treatment options for patients.

As a result of positive growth, various startups are entering the market. For instance, Novela Neurotechnology is a US-based startup that has developed Neureka, a smart platform that uses artificial intelligence to understand and decode neurological activity in the brain. The platform combines neural interfaces and neuromodulation delivery to speed up drug discovery.

North America is anticipated to acquire a market share of about 40% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. Furthermore, government initiatives and increase in the number of research partnerships are boosting the market growth across North America.  Asia Pacific is a growing market due to a shift towards point-of-care healthcare. The increasing number of hospitals in India and China presents a promising market opportunity globally.

Market Competition

Key players in the market include pharmaceutical companies such as Bristol-Myers Squibb, Pfizer, Sanofi, Johnson & Johnson and Roche along with the healthcare providers and technology companies among other global players.

Read More Details@ https://www.futuremarketinsights.com/reports/hypercoagulability-treatment-market

Key Segments Profiled in the Hypercoagulability Treatment Industry Survey

Drugs:

• Heparin
• Warfarin
• Direct Thrombin Inhibitor

Route of Administration:

• Oral
• Injectable

End Users:

• Hospitals
• Speciality Centers